drugset / Trial / NCT02177175

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

NCT02177175

Phase 2 Completed 82 enrolled Memorial Sloan Kettering Cancer Center
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to find out the effects, good and/or bad, of a beta blocker (carvedilol) on heart function during treatment with anti-HER2 medication(s) including trastuzumab (Herceptin).

Timeline

Start
2014-06-24
Primary completion
2021-06-24
Completion
2021-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 25 mg

Indications